创始人杨文龙,仁和药业股份有限公司系在深圳证券交易所挂牌的上市公司。
公司股票代码为:000650,公司的前身系九江化纤股份有限公司。
是1996年经江西省人民政府批准,1996年11月18日,经中国证监会证监发字(1996)318号文批准。
在深圳证券交易所正式挂牌上市的公司,公司主营业务为生产、销售中西药及健康相关产品。
包括胶囊剂、颗粒剂、片剂、栓剂、仁和可立克、优卡丹、妇炎洁、软膏剂、搽剂等药品以及健康相关产品。
经营范围包括中药材种植;药材种苗培植;纸箱生产、销售;计算机软件开发等;
该公司曾获十佳战略合作企业、十强品牌企业等荣誉。
2020年3月18日,仁和药业以150亿元人民币市值位列《2020胡润中国百强大健康民营企业》第97。
Founder Yang Wenlong, Renhe Pharmaceutical Co., Ltd. is a listed company listed on the Shenzhen Stock Exchange.
The company's stock code is: 000650, and the company's predecessor is Jiujiang Chemical Fiber Co., Ltd.
It was approved by the Jiangxi Provincial People's Government in 1996, and on November 18, 1996, it was approved by the China Securities Regulatory Commission's Zheng Jianfazi (1996) No. 318.
The company is officially listed on the Shenzhen Stock Exchange. The company's main business is the production and sales of Chinese and Western medicines and health-related products.
Including capsules, granules, tablets, suppositories, Renhe Kelike, Youkadan, Fuyanjie, ointments, liniments and other medicines and health-related products.
The business scope includes planting of Chinese medicinal materials; cultivation of medicinal material seedlings; production and sales of cartons; computer software development, etc.
The company has won honors such as the Top Ten Strategic Cooperation Enterprises and the Top Ten Brand Enterprises.
On March 18, 2020, Renhe Pharmaceutical ranked 97th in the "2020 Hurun China Top 100 Private Healthcare Enterprises" with a market value of RMB 15 billion.